Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand

被引：0
|
作者：
Sundset, Rune [1 ,2 ]
Haugnes, Hege Sagstuen
Perez, Alexander [1 ]
Engelsen, Ola [1 ]
Fosseide, Ida H. H. [1 ]
Castillejo, Miguel J. [1 ]
Bogsrud, Trond Velde [1 ]
机构：
[1] Universitetssykehuset Nord Norge, Oslo, Norway
[2] UiT Norges Arktiske Univ, Nuklearmedisinsk & Stralebiol Forskningsgrp, Oslo, Norway
来源：
TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING | 2024年 / 144卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：104
相关论文
共 50 条
  • [1] Lu-177 PSMA Radioligand Therapy as Salvage Treatment in Metastatic Castration-Resistant Prostate Cancer
    Kulkarni, H. R.
    Singh, A.
    Schuchardt, C.
    Langbein, T.
    Zhang, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S287 - S288
  • [2] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [3] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024,
  • [4] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
    Ahmadzadehfar, Hojjat
    Schlolaut, Stephan
    Fimmers, Rolf
    Yordanova, Anna
    Hirzebruch, Stefan
    Schlenkhoff, Carl
    Gaertner, Florian C.
    Awang, Zool Hilmi
    Hauser, Stefan
    Essler, Markus
    ONCOTARGET, 2017, 8 (61) : 103108 - 103116
  • [5] 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
    Derlin, Thorsten
    Widjaja, Liam
    Werner, Rudolf A.
    Bengel, Frank M.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 54 - 58
  • [6] Treatment efficacy and safety of 177Lu-PSMA Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer
    Langbein, T.
    Retz, M.
    D'Alessandria, C.
    Grigorascu, S.
    Hansen, K.
    Wester, H.
    Gschwend, J.
    Weber, W.
    Eiber, M.
    Tauber, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S132 - S133
  • [7] Effectiveness of 177Lu PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
    Gunalp, Bengul
    Emer, Mustafa
    Ozaydin, Sukru
    Alagoz, Engin
    Ince, Semra
    Ayan, Asli
    Alkan, Sumeyye
    Mahmudov, Sarkhan
    Okuyucu, Kursat
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [8] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Seifert, Robert
    Boegemann, Martin
    LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
  • [9] Response to [177Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
    Zisser, Lucia
    Yu, Josef
    Oszwald, Andre
    Wollenweber, Tim
    Kretschmer-Chott, Elisabeth
    Grubmueller, Bernhard
    Kramer, Gero
    Shariat, Shahrokh F.
    Mitterhauser, Markus
    Vraka, Chrysoula
    Hacker, Marcus
    Haug, Alexander R.
    Rasul, Sazan
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (11) : 1113 - 1120
  • [10] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
12345